Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Liabilities and Shareholders Equity (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $25.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 26.58% to $25.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $180.6 million through Dec 2025, down 28.06% year-over-year, with the annual reading at $25.8 million for FY2025, 26.58% down from the prior year.
  • Liabilities and Shareholders Equity hit $25.8 million in Q4 2025 for Insight Molecular Diagnostics, down from $43.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $177.4 million in Q2 2021 to a low of $25.8 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $98.4 million across 5 years, with a median of $82.2 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 191.37% in 2021 and later crashed 53.16% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $159.6 million in 2021, then tumbled by 37.27% to $100.1 million in 2022, then dropped by 25.18% to $74.9 million in 2023, then plummeted by 53.16% to $35.1 million in 2024, then fell by 26.58% to $25.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for IMDX at $25.8 million in Q4 2025, $43.9 million in Q3 2025, and $50.5 million in Q2 2025.